Abstract:Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors. We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors. Methods In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncology Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 weeks of treatment with erlotinib or gefitinib. We used a computer-generated sequence to randomly allocate patients (2: 1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care. Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2). Investigators, patients, and the trial sponsor were masked to treatment assignment. The primary endpoint was overall survival (from date of randomisation to death), analysed on an intention-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT00656136. Findings Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo). Median overall survival was 10.8 months (95% CI 10.0-12.0) in the afatinib group and 12.0 months (10.2-14.3) in the placebo group (hazard ratio 1.08, 95% CI 0.86-1.35; p=0.74). Median progression-free survival was longer in the afatinib group (3.3 months, 95% CI 2.79-4.40) than it was in the placebo group (1.1 months, 0.95-1.68; hazard ratio 0.38, 95% CI 0.31-0.48; p<0.0001). No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group. Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group. The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3). These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2. Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group. We recorded two possibly treatment-related deaths in the afatinib group. Interpretation Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 weeks of previous EGFR tyrosine-kinase inhibitor treatment.

Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial

P2.06-013 Afatinib in Patients with Advanced HER2 Mutation-Positive (M+) NSCLC Previously Treated with Chemotherapy: Topic: Phase II + NK

Surgical Resection of Lung Adenocarcinoma Without EGFR Mutation after Neoadjuvant Gefitinib Treatment

Low Dose of Apatinib in Treating Chemotherapy and EGFR-TKI Refractory Non-Small Cell Lung Cancer A Case Report

Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer

Radical resection in a patient with stage IIIA non-small cell lung cancer with the EGFR exon 19 deletion mutation after neoadjuvant targeted therapy with osimertinib: a case report

Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report

Video-assisted Thoracoscopic Right Upper Sleeve Lobectomy after Neoadjuvant Chemotherapy for Central Non-Small Cell Lung Cancer

Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non-small cell lung cancer

Salvage surgery following tyrosine kinase inhibitor treatment for advanced non-small cell lung cancer

Survival Outcomes of Neoadjuvant Therapy Followed by Sleeve Lobectomy in Non-Small Cell Lung Cancer

Sleeve lobectomy versus pneumonectomy following neoadjuvant therapy in patients with non-small cell lung cancer

Neoadjuvant Afatinib for stage III EGFR -mutant non-small cell lung cancer: a phase II study

Feasibility of Surgical Resection After Induction Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for N2 Lung Adenocarcinomas

A case of multiple primary lung adenocarcinoma with a CD74‐NRG1 fusion protein and HER2 mutation benefit from combined target therapy

Robotic Assisted Extended Sleeve Lobectomy After Neoadjuvant Chemotherapy

Surgery for Advanced Non-Small Cell Lung Cancer Patient after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Neoadjuvant Therapy.

Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Recurrent Adenosquamous Carcinoma of the Lung after Resection

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy